Skip to main content
. 2022 Nov 3;5(11):e2239884. doi: 10.1001/jamanetworkopen.2022.39884

Table. Demographic Characteristics of Participants in All Phase 1 Trials, Industry-Funded Trials, and Trials Conducted at Academic Centersa.

Characteristic Participants, No. (%)
American Indian or Alaska Native Asian or Pacific Islander Black Hispanic or Latinx White
Phase 1 trials
All (N = 8309) 23 (0.3) 371 (4.5) 514 (6.2) 401 (7.9) 7154 (86.1)
2000-2011 (n = 3245) 10 (0.3) 121 (3.7) 244 (7.5) 161 (9.0) 2780 (85.7)
2012-2018 (n = 5063) 13 (0.3) 151 (3.0) 270 (5.3) 240 (7.3) 4374 (86.4)
Industry trials
All (n = 7365) 19 (0.3) 332 (4.5) 414 (5.6) 359 (8.3) 6387 (86.7)
2000-2011 (n = 2737) 10 (0.4) 106 (3.9) 178 (6.5) 131 (9.4) 2370 (86.6)
2012-2018 (n = 4628) 9 (0.2) 226 (4.9) 236 (5.1) 228 (7.7) 4017 (86.8)
Academic center trials
All (n = 5951) 16 (0.3) 221 (3.7) 374 (6.3) 276 (7.8) 5175 (87.0)
2000-2011 (n = 1806) 7 (0.4) 68 (3.8) 149 (8.3) 62 (7.4) 1536 (85.0)
2012-2018 (n = 4145) 9 (0.2) 153 (3.7) 225 (5.4) 214 (8.0) 3639 (87.8)
a

Not every trial that reported race reported ethnicity. The number of participants in trials that reported ethnicity was 5076, which is the denominator for all phase 1 trials (all trials in 2000-2011 [n = 1792] and 2012-2018 [n = 3295], all industry-funded trials in 2000-2011 [n = 138] and 2012-2018 [n = 2958], and all trials at academic centers in 2000-2011 [n = 841] and 2012-2018 [n = 2682]).